Zobrazeno 1 - 10
of 245
pro vyhledávání: '"Ana, Rovira"'
Autor:
Sara Santana-Hernández, Jesús Suarez-Olmos, Sonia Servitja, Pau Berenguer-Molins, Marcel Costa-Garcia, Laura Comerma, Anna Rea, Julia Perera-Bel, Silvia Menendez, Oriol Arpí, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo, Iñaki Comino-Méndez, Javier Pascual, Emilio Alba, Miguel López-Botet, Federico Rojo, Ana Rovira, Joan Albanell, Aura Muntasell
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-15 (2024)
Abstract Background The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural Killer (TI-NK) cells ca
Externí odkaz:
https://doaj.org/article/5bc22c2f73dc42618cc14ecab70aa357
Autor:
Lilian Marie Boll, Júlia Perera-Bel, Alejo Rodriguez-Vida, Oriol Arpí, Ana Rovira, Núria Juanpere, Sergio Vázquez Montes de Oca, Silvia Hernández-Llodrà, Josep Lloreta, M. Mar Albà, Joaquim Bellmunt
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and can result in complete remissions even at advanced stages of the disease. However, only a small fraction of patients respond to the treatment. To better understand w
Externí odkaz:
https://doaj.org/article/9d09f1fe0eee43aebdca7bfe8d908283
Autor:
Birlipta Pattanayak, Iris Garrido-Cano, Anna Adam-Artigues, Eduardo Tormo, Begoña Pineda, Paula Cabello, Elisa Alonso, Begoña Bermejo, Cristina Hernando, María Teresa Martínez, Ana Rovira, Joan Albanell, Federico Rojo, Octavio Burgués, Juan Miguel Cejalvo, Ana Lluch, Pilar Eroles
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial–mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of
Externí odkaz:
https://doaj.org/article/116915f38b83493fb827155096227e7d
Autor:
David Tamborero, Carlota Rubio-Perez, Jordi Deu-Pons, Michael P. Schroeder, Ana Vivancos, Ana Rovira, Ignasi Tusquets, Joan Albanell, Jordi Rodon, Josep Tabernero, Carmen de Torres, Rodrigo Dienstmann, Abel Gonzalez-Perez, Nuria Lopez-Bigas
Publikováno v:
Genome Medicine, Vol 10, Iss 1, Pp 1-8 (2018)
Abstract While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform th
Externí odkaz:
https://doaj.org/article/0e69b340b3c34623b79163ba6ddce679
Autor:
Max Hardy-Werbin, Pedro Rocha, Oriol Arpi, Álvaro Taus, Lara Nonell, Xavier Durán, Xavier Villanueva, Deborah Joseph-Pietras, Luke Nolan, Sarah Danson, Richard Griffiths, Miguel Lopez-Botet, Ana Rovira, Joan Albanell, Christian Ottensmeier, Edurne Arriola
Publikováno v:
OncoImmunology, Vol 8, Iss 6 (2019)
Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines in two cohorts of S
Externí odkaz:
https://doaj.org/article/a1ead5721a954201bf1312e65ba8f204
Autor:
Anna Adam-Artigues, Enrique J. Arenas, Alex Martínez-Sabadell, Fara Brasó-Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernando, María Teresa Martínez, Juan Carbonell-Asins, Soraya Simón, Jesús Poveda, Santiago Moragón, Sandra Zazo, Débora Martínez, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Begoña Bermejo, Ana Lluch, Aleix Prat, Joaquín Arribas, Pilar Eroles, Juan Miguel Cejalvo
Publikováno v:
Science Advances
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
Scientia
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
Scientia
Breast cancer; Heterodimerization Cáncer de mama; Heterodimerización Càncer de mama; Heterodimerització Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06fb8c5eed3e6e740807833312138fdd
http://hdl.handle.net/2445/197295
http://hdl.handle.net/2445/197295
Autor:
Aura Muntasell, Miguel López-Botet, Ignacio Melero, Joan Albanell, Pedro Berraondo, Ana Rovira, Laura Comerma, Silvia Menéndez, Maria C. Ochoa, Manel Juan, Francesc Balaguer, Michelle Ataya, Roberto Lozano-Rodríguez, Anna Rea, Marcel Costa-Garcia, Sara Santana-Hernández, Mariona Cabo
Enhancing natural killer (NK) cell–based cancer immunotherapy by overcoming immunosuppression is an area of intensive research. Here, we have demonstrated that the anti-CD137 agonist urelumab can overcome TGFβ-mediated inhibition of human NK-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55eece933a417d140ac1db0cf999894f
https://doi.org/10.1158/2326-6066.c.6550737
https://doi.org/10.1158/2326-6066.c.6550737
Autor:
Aura Muntasell, Miguel López-Botet, Ignacio Melero, Joan Albanell, Pedro Berraondo, Ana Rovira, Laura Comerma, Silvia Menéndez, Maria C. Ochoa, Manel Juan, Francesc Balaguer, Michelle Ataya, Roberto Lozano-Rodríguez, Anna Rea, Marcel Costa-Garcia, Sara Santana-Hernández, Mariona Cabo
Supplementary Tables 1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::449e4c5b3d758f00fca862c9c9a65b7f
https://doi.org/10.1158/2326-6066.22544733
https://doi.org/10.1158/2326-6066.22544733
Autor:
Aura Muntasell, Miguel López-Botet, Ignacio Melero, Joan Albanell, Pedro Berraondo, Ana Rovira, Laura Comerma, Silvia Menéndez, Maria C. Ochoa, Manel Juan, Francesc Balaguer, Michelle Ataya, Roberto Lozano-Rodríguez, Anna Rea, Marcel Costa-Garcia, Sara Santana-Hernández, Mariona Cabo
Figures S1, S2, S3, S4, S5, S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7a548f5f74c4c2013976fb00126d05a
https://doi.org/10.1158/2326-6066.22544736
https://doi.org/10.1158/2326-6066.22544736
Autor:
Miguel López-Botet, Joan Albanell, Ana Lluch, Carlos Vilches, Ana Rovira, Pilar Eroles, Sara Santana-Hernández, Laura Comerma, Laura Soria, María Martínez-García, Andrea Vera, Gemma Heredia, María Teresa Martínez, Ignasi Tusquets, Laia Serrano, Manuela Moraru, Oriol Arpí, Marcel Costa-García, Federico Rojo, Sandra Pérez-Buira, Begoña Bermejo, Mariona Cabo, Sònia Servitja, Aura Muntasell
Natural killer (NK) cells can orchestrate effective antitumor immunity. The presence of tumor-infiltrating NK cells in diagnostic biopsies predicts pathologic complete response (pCR) to HER2-specific therapeutic antibodies in patients with primary br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e5efee955b03a6fc572b6e8fe6efaed
https://doi.org/10.1158/2326-6066.c.6550095.v1
https://doi.org/10.1158/2326-6066.c.6550095.v1